4.5 Article

Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients

期刊

BREAST CANCER RESEARCH AND TREATMENT
卷 131, 期 2, 页码 437-444

出版社

SPRINGER
DOI: 10.1007/s10549-011-1422-5

关键词

Inflammatory breast cancer; Locally advanced breast cancer; Tumor emboli; Tumor subtypes; Hormone receptors; Growth factor receptors; Overall survival; Disease-free survival

类别

资金

  1. New Mexico State IBC [532]
  2. University of New Mexico Clinical and Translational Science [CTSA 1ULRR031977-01]
  3. UICC ICRETT [ICR/09/043]

向作者/读者索取更多资源

Inflammatory breast cancer (IBC) shows a high incidence in Tunisia and Egypt but epidemiological and molecular characteristics have not been described in Algeria. We compared 117 IBC and 59 non-IBC locally advanced breast cancers (LABC), for estrogen and progesterone receptors, HER2, and EGFR protein expression by immunohistochemistry, and HER2 gene amplification by chromogenic in situ hybridization. Demographic, clinico-pathological, and molecular variables were compared with chi-square and Fisher's exact tests to test for significance (P < 0.05, two-tailed). Overall survival (OS) and disease-free survival (DFS) were plotted using Kaplan-Meier curves and compared using the log-rank test. Tumor emboli were detected in 77% of IBC. Palpable masses were found in all LABC but only in 32% of IBC (P < 0.001). Recurrences were higher in LABC than in IBC (48 vs. 35%; P = 0.14) but OS was worse in IBC (68 vs. 71%; P = 0.06). There were no significant differences between IBC and LABC by demographics or by clinico-pathological parameters. The majority of IBC and LABC tumors were luminal A (62 and 64%), followed by basal (similar to 18%, each), triple negative (similar to 18%, each), and HER2+ (similar to 10%, each) subtypes. In multivariate analyses, grade was associated with worse OS (P = 0.04), and DFS (P < 0.001) in IBC; chemo- and radio-therapy were associated with improved OS and DFS, respectively (P < 0.05 for each) in LABC. In conclusion, IBC in Algeria shows similar characteristics to IBC described for Egypt and Tunisia with subtle molecular differences. Current therapeutic treatments were not very effective in this population and new approaches are much needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma Phase 1b Results From the JAVELIN Solid Tumor Trial

Raffit Hassan, Anish Thomas, John J. Nemunaitis, Manish R. Patel, Jaafar Bennouna, Franklin L. Chen, Jean-Pierre Delord, Afshin Dowlati, Samith T. Kochuparambil, Matthew H. Taylor, John D. Powderly, Ulka N. Vaishampayan, Claire Verschraegen, Hans Juergen Grote, Anja von Heydebreck, Kevin Chin, James L. Gulley

JAMA ONCOLOGY (2019)

Editorial Material Oncology

Hypofractionated Nodal Irradiation for Breast Cancer A Case for Caution

Vincent Vinh-Hung, Nam P. Nguyen, Claire Verschraegen

JAMA ONCOLOGY (2019)

Meeting Abstract Oncology

First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.

Bhavana Konda, Sherise C. Rogers, Cassandra Natalie Grenade, Claire F. Verschraegen, Ye Zhou, Ashima Goyal, Mona Natwa, Chadwick Wright, Akram Hussein, Hallie Barr, Dramane Konate, Andrew Brown, Rochelle Batdorf, Bonnie Williams, Songzhu Zhao, Lai Wei, Manisha H. Shah

JOURNAL OF CLINICAL ONCOLOGY (2019)

Meeting Abstract Oncology

Low dose enzalutamide in metastatic castration-resistant prostate cancer: A retrospective Caribbean study.

Vincent Vinh-Hung, Kadiatou Diakite, Clarisse Joachim, Stefanos Bougas, Cristina Ioana Furtos, Jean-Marc Rakotonarivo, Wadah Lababidi, Eva Papadopoulou, Patrick Escarmant, Jacqueline Veronique-Baudin, Claire F. Verschraegen

JOURNAL OF CLINICAL ONCOLOGY (2019)

Article Oncology

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

Mingjia Li, Daniel Spakowicz, Jarred Burkart, Sandip Patel, Marium Husain, Kai He, Erin M. Bertino, Peter G. Shields, David P. Carbone, Claire F. Verschraegen, Carolyn J. Presley, Gregory A. Otterson, Kari Kendra, Dwight H. Owen

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Article Biochemistry & Molecular Biology

Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins

April M. Averill, Hibba Tul Rehman, Joseph W. Charles, Timothy A. Dinh, Karamatullah Danyal, Claire F. Verschraegen, Gary S. Stein, Wolfgang R. Dostmann, Jon E. Ramsey

JOURNAL OF CELLULAR BIOCHEMISTRY (2019)

Article Oncology

Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer

Ming Yin, Jing Zhao, Paul Monk, Douglas Martin, Edmund Folefac, Monika Joshi, Ning Jin, Amir Mortazavi, Claire Verschraegen, Steven Clinton

CANCER MEDICINE (2020)

Article Multidisciplinary Sciences

Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance

Emily L. Giddings, Devin P. Champagne, Meng-Han Wu, Joshua M. Laffin, Tina M. Thornton, Felipe Valenca-Pereira, Rachel Culp-Hill, Karen A. Fortner, Natalia Romero, James East, Phoebe Cao, Hugo Arias-Pulido, Karatatiwant S. Sidhu, Brian Silverstrim, Yoonseok Kam, Shana Kelley, Mark Pereira, Susan E. Bates, Janice Y. Bunn, Steven N. Fiering, Dwight E. Matthews, Robert W. Robey, Domink Stich, Angelo D'Alessandro, Mercedes Rincon

Summary: Chemotherapy is the standard treatment for most cancers worldwide, but chemoresistance due to ABC transporters is a significant challenge. The study highlights the role of mitochondrial respiration in supplying ATP for ABC transporters, and how inhibiting mitochondrial respiration can overcome chemoresistance. Development of MCJ mimetics offers a potential alternative strategy for treating multiple cancers by targeting this mechanism.

NATURE COMMUNICATIONS (2021)

Article Oncology

Differential effects of CD20+B cells and PD-L1+immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients

Hugo Arias-Pulido, Ashley Marie Cimino-Mathews, Nabila Chaher, Clifford Ray Qualls, Nancy Joste, Cecile Colpaert, Jonathan Douglas Marotti, Mary Dickinson Chamberlin, Maxwell Gabriel Foisey, Eric Robert Prossnitz, Leisha Ann Emens, Steven Fiering

Summary: This study evaluated epidemiologic and immune factors associated with pCR, BCSS, and DFS outcomes in IBC and LABC patients. High TILs, PD-L1(+) carcinoma cells, and combined CD20(+) and PD-L1(+) carcinoma cells were correlated with pCR in both IBC and LABC patients, with pCR correlating with improved BCSS and DFS outcomes.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Article Oncology

Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer

Daniel Alonso-Miguel, Guillermo Valdivia, Diego Guerrera, Maria Dolores Perez-Alenza, Stanislav Pantelyushin, Angela Alonso-Diez, Veronique Beiss, Steven Fiering, Nicole F. Steinmetz, Maria Suarez-Redondo, Johannes Vom Berg, Laura Pena, Hugo Arias-Pulido

Summary: In situ eCPMV immunotherapy has demonstrated anti-tumor efficacy and improved survival in IMC patients, suggesting its potential as a groundbreaking immunotherapy for both canine IMC and human IBC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Editorial Material Cell Biology

Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes

Daniel Alonso-Miguel, Steven Fiering, Hugo Arias-Pulido

Summary: Inflammatory breast cancer (IBC) is a highly metastatic form of breast cancer with no specific treatments. Recent research shows that combining immune therapy with chemotherapy can improve the prognosis of IBC patients. Direct injection of immunostimulatory agents into the tumor is proposed as a safe, effective, and cost-effective option for improving outcomes in IBC patients.
Article Cell Biology

Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Induces Local and Systemic Antitumor Efficacy in Canine Mammary Cancer Patients

Guillermo Valdivia, Daniel Alonso-Miguel, Maria Dolores Perez-Alenza, Anna Barbara Emilia Zimmermann, Evelien Schaafsma, Fred W. Kolling, Lucia Barreno, Angela Alonso-Diez, Veronique Beiss, Jessica Fernanda Affonso de Oliveira, Maria Suarez-Redondo, Steven Fiering, Nicole F. Steinmetz, Johannes vom Berg, Laura Pena, Hugo Arias-Pulido

Summary: This study explores a novel immunotherapy approach and shows that intratumoral immunotherapy with eCPMV can effectively reduce tumor volume in breast cancer without any adverse effects. The results suggest that this method has the potential to improve treatment outcomes for breast cancer patients.
Meeting Abstract Oncology

Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

B. Hrinczenko, D. Spigel, N. Iannotti, H. P. Safran, M. H. Taylor, J. Bennouna, S. Goel, J. Leach, D. J. Wong, K. Kelly, C. Verschraegen, M. Bajars, J. Manitz, M. Ruisi, J. L. Gulley

ANNALS OF ONCOLOGY (2019)

Meeting Abstract Oncology

Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy.

Daniel Spakowicz, Marium Husain, Gabriel Tinoco, Sandip H. Patel, Jarred Thomas Burkart, Claire F. Verschraegen, Kari Lynn Kendra, Sarah Hoffman, Jennifer Philippon, Dionisia Marie Quiroga, Gregory Alan Otterson, Dwight Hall Owen

JOURNAL OF CLINICAL ONCOLOGY (2019)

Letter Medicine, General & Internal

Enzalutamide in Metastatic Prostate Cancer

Ming Yin, Vincent Vinh-Hung, Claire Verschraegen

NEW ENGLAND JOURNAL OF MEDICINE (2019)

暂无数据